Breast Diseases: Clinical Trials

6856 completed, 2080 unknown, 2014 recruiting, 1269 terminated. 4183 Not applicable, 3993 Phase 2, 2197 Phase 1, 1354 Phase 3, 294 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	4183	Completed 2051, Recruiting 620, Unknown 588, Active not recruiting 293, Not yet recruiting 252, Terminated 205, Withdrawn 134, Enrolling by invitation 28, Suspended 12
Phase 2	3993	Completed 1688, Terminated 595, Recruiting 532, Unknown 525, Active not recruiting 282, Not yet recruiting 188, Withdrawn 166, Enrolling by invitation 10, Suspended 7
Phase 1	2197	Completed 1061, Terminated 326, Recruiting 298, Active not recruiting 174, Unknown 166, Withdrawn 93, Not yet recruiting 59, Suspended 13, Enrolling by invitation 7
Phase 3	1354	Completed 665, Unknown 190, Recruiting 164, Active not recruiting 135, Terminated 109, Not yet recruiting 52, Withdrawn 30, Suspended 7, Enrolling by invitation 2
Phase 4	294	Completed 141, Unknown 63, Recruiting 33, Not yet recruiting 21, Terminated 18, Withdrawn 10, Active not recruiting 7, Enrolling by invitation 1
Early Phase 1	201	Completed 103, Recruiting 26, Unknown 23, Withdrawn 20, Terminated 18, Not yet recruiting 5, Active not recruiting 4, Enrolling by invitation 2

Follow Breast Diseases: new trials by email Literature Review of Breast Diseases trials Research Report on Breast Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Application of Multimodal MRI-based Radiomics in Histological Grading and Prognostic Assessment of Breast Cancer DCE-MRI - Breast Cancer, Breast Cancer With Low to Intermediate HER2 Expression		Not yet recruiting	Hao Xu	400	2028-01-01	2026-02-05
Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer Resistant Potato Starch, Placebo control - Breast Cancer, HER-2 Positive Breast Cancer	Not applicable	Not yet recruiting	University of Vermont Medical Center	12	2027-10-01	2026-02-12
Developing and Testing the Efficacy of AI-Chatbot-Based AIAI-Chatbot CalmMindRecoveryJourney delivering BMS-MC therapy - Breast Cancer	Not applicable	Not yet recruiting	National Taiwan University Hospital	68	2027-08-01	2026-08-27
EmpowerHer: Hybrid Digital Intervention for Breast Cancer Survivors EmpowerHer Hybrid Program - Breast Cancer, Cancer Survivors	Not applicable	Not yet recruiting	University of Valencia	147	2027-07-01	2026-06-30
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer	Phase 2	Not yet recruiting	University of California, San Diego	150	2027-07-01	2026-07-27
Korea Post Marketing Surveillance (PMS) Study of Talzenna® Talzenna - Breast Neoplasms		Withdrawn	Pfizer		2027-06-01	2026-09-14
HEADWATERS: Gemcitabine vs Paclitaxel in Metastatic Triple-Negative Breast Cancer in Women of African Ancestry. Gemcitabine (1000 mg/m^2), Paclitaxel 80 mg/m2 weekly - Triple Negative Breast Cancer, Metastatic Triple-negative Breast Cancer	Phase 2	Not yet recruiting	The University of The West Indies	750	2027-06-01	2026-09-22
A Master Trial Assessing the Technical Feasibility of First-In-Human Real-Time Image Guided Radiation Therapy Methods Real-Time Image Guided Radio Therapy (IGRT) - Cancer	Not applicable	Not yet recruiting	University of Sydney	40	2027-06-01	2026-05-20
Molecular Breast Imaging (MBI)-Guided Biopsy Molecular Breast Imaging, MBI-guided biopsy - Breast Cancer Detection, Breast Neoplasm	Not applicable	Not yet recruiting	Smart Breast Corp.	250	2027-06-01	2025-08-11
Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) [18F]FMISO-PET with contrast-enhanced MRI - Triple Negative Breast Cancer	Early Phase 1	Recruiting	University of Alabama at Birmingham	20	2027-06-01	2026-08-17
Multi-4SCAR-T Therapy Targeting Breast Cancer 4SCAR T cells - Breast Cancer	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	100	2027-06-01	2026-08-26
Early Intervention Juzo Compression Sleeve and Glove, Compression Sleeve Sensor - Breast Cancer, Breast Cancer Treatment Related Lymphedema	Not applicable	Not yet recruiting	Massachusetts General Hospital	40	2027-05-01	2026-07-13
Cancer Awareness Among Syrian Migrants PMT-Based Cancer Screening Educational Intervention, PMT-Based Cancer Screening Education Program - Breast Cancer Screening, Cervical Cancer Screening	Not applicable	Not yet recruiting	Toros University	30	2027-03-09	2026-10-15
TROPION Breast Respond in 1L TNBC Dato-DXd - Unresectable Triple-negative Breast Cancer, Metastatic Triple-negative Breast Cancer		Not yet recruiting	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	400	2027-03-01	2026-10-09
Prehabilitation for Improving Outcomes in Breast Cancer Patients Undergoing Neoadjuvant Systemic Treatment and Surgery Aerobic Exercise, Bioelectric Impedance Analysis, Consultation - Breast Carcinoma	Not applicable	Not yet recruiting	City of Hope Medical Center	20	2027-02-24	2026-09-15
Role of Artificial Intelligence in Breast Cancer Screening Via Mammography Transpara software - Breast Cancer	Not applicable	Not yet recruiting	Centre Antoine Lacassagne	1222	2027-01-31	2026-10-20
Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT) Radiation Therapy, Standard of Care Radiation Therapy, No Intervention - Breast Cancer	Phase 3	Not yet recruiting	NRG Oncology	5270	2027-01-30	2026-09-30
Implementing a Digital Alcohol Intervention to Raise Women's Awareness of Alcohol-related Breast Cancer Risk During Routine Screening Visits Sobriety Digital Intervention - Breast Cancer, Alcohol Drinking	Not applicable	Not yet recruiting	University of Miami	36	2027-01-04	2026-10-20
A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) Carboplatin, Paclitaxcel, Pembrolizumab - Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes	Phase 2	Recruiting	Medical University of South Carolina	55	2027-01-01	2026-10-15
Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients Core Intervention, EHR Integration (On v. Off), Weekly Coaching - Metastatic Breast Cancer, Metastatic Breast Cancer (MBC)	Not applicable	Not yet recruiting	Northwestern University	224	2027-01-01	2026-10-01

Showing 20 of 14508. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (13489)  ·  Triple Negative Breast Neoplasms (1199)  ·  Neoplasms (769)  ·  Ovarian Neoplasms (696)  ·  Colorectal Neoplasms (607)  ·  Lung Neoplasms (605)  ·  Neoplasm Metastasis (601)  ·  Prostatic Neoplasms (571)  ·  Carcinoma, Non-Small-Cell Lung (554)  ·  Pancreatic Neoplasms (393)  ·  Melanoma (372)  ·  Stomach Neoplasms (368)  ·  Colonic Neoplasms (337)  ·  Motor Activity (298)  ·  Breast Neoplasms, Male (286)

Broader conditions

Skin and Connective Tissue Diseases (14508)  ·  Skin Diseases (14494)  ·  Neoplasms by Site (14347)  ·  Neoplasms (13612)  ·  Pathological Conditions, Signs and Symptoms (2046)  ·  Urogenital Diseases (1598)  ·  Neoplasms by Histologic Type (1518)  ·  Urogenital Neoplasms (1452)  ·  Genital Diseases (1384)  ·  Pathologic Processes (1379)  ·  Digestive System Diseases (1307)  ·  Female Urogenital Diseases and Pregnancy Complications (1288)  ·  Digestive System Neoplasms (1271)  ·  Female Urogenital Diseases (1225)

Interventions

Paclitaxel (653)  ·  Trastuzumab (650)  ·  Cyclophosphamide (617)  ·  Docetaxel (508)  ·  Capecitabine (450)  ·  Letrozole (386)  ·  Carboplatin (363)  ·  Fulvestrant (342)  ·  Doxorubicin (327)  ·  Tamoxifen (284)  ·  pembrolizumab (272)  ·  Anastrozole (252)  ·  Epirubicin (236)  ·  exemestane (232)  ·  Radiotherapy (226)

Sponsors

National Cancer Institute (NCI) (308)  ·  Fudan University (258)  ·  M.D. Anderson Cancer Center (244)  ·  Memorial Sloan Kettering Cancer Center (237)  ·  AstraZeneca (185)  ·  Hoffmann-La Roche (183)  ·  Novartis Pharmaceuticals (181)  ·  Pfizer (160)  ·  Mayo Clinic (152)  ·  Dana-Farber Cancer Institute (143)  ·  Alliance for Clinical Trials in Oncology (93)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (93)  ·  Eli Lilly and Company (92)  ·  City of Hope Medical Center (90)  ·  Washington University School of Medicine (87)

Countries

United States (6256)  ·  China (1777)  ·  France (1223)  ·  Spain (948)  ·  Canada (927)  ·  Italy (886)  ·  United Kingdom (771)  ·  Germany (685)  ·  South Korea (610)  ·  Belgium (568)  ·  Australia (445)  ·  Taiwan (397)  ·  Netherlands (392)  ·  Turkey (Türkiye) (391)  ·  Brazil (344)

Top investigators

Norman Wolmark, MD (36)  ·  Edith A. Perez, MD (18)  ·  Biyun Wang, Professor (15)

Results publications

PMID 38979716, PMID 34037241, PMID 29522361, PMID 32450725, PMID 40443562, PMID 39606939, PMID 40207789, PMID 41170811, PMID 22508812, PMID 24529560, PMID 32101663, PMID 33084020, PMID 39024777, PMID 42334791, PMID 18355913, PMID 22649152, PMID 25071111, PMID 26101239, PMID 26348120, PMID 26438146, PMID 27432417, PMID 28898379, PMID 30032196, PMID 30207593, PMID 30711522, PMID 32379297, PMID 32987448, PMID 33307491, PMID 34252375, PMID 35594464, PMID 39613746, PMID 40421669, PMID 12393820, PMID 15894097, PMID 19903919, PMID 20299316, PMID 21247627, PMID 21376385, PMID 21796368, PMID 21880792, PMID 22198468, PMID 23871490, PMID 23902874, PMID 24091623, PMID 24682463, PMID 24881463, PMID 25092775, PMID 25439688, PMID 27367583, PMID 28057664

NIH funding

2023 (101), 2016 (67), 2019 (57), 2014 (54), 2017 (54), 2025 (52), P30CA033572 (52), 2018 (49), 2015 (46), 2008 (37), P30CA015083 (36), 2009 (34), 2005 (32), P30CA016672 (30), P30CA043703 (30)